Cargando…
Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America
BACKGROUND: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders, leading to the progressive accumulation of glycosaminoglycans (GAGs) and the subsequent compromising of tissues and organ malfunction. Although incurable, most types of MPS can be treated with enzyme replacement ther...
Autores principales: | Solano, MarthaL., Fainboim, Alejandro, Politei, Juan, Porras-Hurtado, Gloria L., Martins, Ana Maria, Souza, Carolina F. Moura, Koch, Felipe Mendez, Amartino, Hernan, Satizábal, Jose Maria, Horovitz, Dafne D.G., Medeiros, Paula F.V., Honjo, Rachel S., Lourenço, Charles M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047015/ https://www.ncbi.nlm.nih.gov/pubmed/32140416 http://dx.doi.org/10.1016/j.ymgmr.2020.100572 |
Ejemplares similares
-
Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes
por: Politei, Juan, et al.
Publicado: (2021) -
Laryngeal, Tracheal, and Bronchial Disease in the Mucopolysaccharidoses: Endoscopic Study
por: Pires de Mello, Paulo, et al.
Publicado: (2020) -
Otolaryngologists and the Early Diagnosis of Mucopolysaccharidoses: A Cross-Sectional Study
por: Torres, Danielle de Araujo, et al.
Publicado: (2019) -
Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina
por: Cabrera, Gustavo, et al.
Publicado: (2017) -
Anesthesiological risks in mucopolysaccharidoses
por: Moretto, Alessandra, et al.
Publicado: (2018)